Untitled 1 1024x538 1 captis executive search management consulting leadership board services

St. Elizabeth Healthcare Enhances Access To Cardiac Care With Multi-specialty Outpatient Building

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

Expected to be completed in November 2021, the new HVI building in Edgewood will bring more than 30 multi-specialty physicians and 30 advanced practice providers to one, centralized location.

“We opened the Heart & Vascular Institute six years ago with the goal of improving access to quality cardiovascular care for individuals in our region, and since then, we’ve made impressive strides in service offerings and patient outcomes,” said D.P. Suresh, MD, Cardiologist and Executive Medical Director of the St. Elizabeth HVI. “Our team of specialists leverages innovative and truly transformative technologies to enhance the quality of life for patients with serious heart conditions.”

When the HVI opened in 2015, St. Elizabeth set a goal to work with the community to decrease heart-related deaths 25 percent by 2025, coining the phrase “25 by 25.” At the end of 2020, the System reported a 12.57 percent decrease, based on the most recently available data from the Centers for Disease Control, tracking on target to meet the goal.

Over the last six years, St. Elizabeth has added specialists in every field of heart care and adopted leading-edge technology, including pacemakers small enough to fit inside the heart, heart valves that can be replaced without open heart surgery and implantable heart pumps that extend life for patients with heart failure. St. Elizabeth also achieved accreditation as a Cardiovascular Center of Excellence from the American Heart Association, and is the only hospital in Greater Cincinnati to hold this distinction.

“Our focus on heart health and cardiac care allows us to effectively fight heart disease, right in our own backyard,” said Victor Schmelzer, MD, Cardiac Surgeon and Medical Director at the HVI. “It’s rewarding to see so many different moving pieces — increased access to care, efficient processes, enhanced technology, partnerships with pre-hospital partners and community education initiatives — come together to achieve one, crucial goal.”

In order to provide exceptional care all under one roof, the new HVI facility in Edgewood will include the following medical specialists and services:

  • Cardiology
  • Cardiac electrophysiology
  • Cardiac surgery
  • Cardiac rehabilitation
  • Outpatient cath lab
  • Advanced Heart Failure Management Center
  • Structural Heart and Valve Center
  • Cardiac diagnostic services
  • Cardiovascular Genetics
  • Cardiac Clinical Trials
  • On-site lab

In addition to St. Elizabeth’s investment in state-of-the-art heart care facilities, treatment options and cardiovascular specialists, the network has also built partnerships with pre-hospital care providers in the region, including the Independence Fire Department.

“St. Elizabeth has been a true partner of the Independence Fire Department, allowing us to work together to improve patient outcomes in our community,” said Phil Dietz, Assistant Fire Chief and EMS Director for Independence Fire Department. “With St. Elizabeth resources and our capabilities, we reduce the time between the first EMS contact to artery-opening care at the hospital, which is critical to saving lives.”

St. Elizabeth also provides post-care reports to all the pre-hospital care providers in the region. These reports allow the organization to review each patient encounter and determine which objectives it met and which it can improve upon, creating a culture of continuous improvement.

Ratona Harr, owner of Full Body Fitness & Yoga in Northern Kentucky, experienced this continuum of care after facing an unexpected heart attack while teaching a group fitness class.

“When I had a widowmaker heart attack, I knew that the team of doctors and nurses at St. Elizabeth were fighting for me,” said Harr. “The quick and responsive care was nothing short of phenomenal — they saved my life. I gain a deeper appreciation for St. Elizabeth, their medical team and staff through every step of my healing process.”

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

Burgeoning Demand for MRI-guided Radiation Therapy Systems Market to Fuel Market Growth Thorough the COVID-19 Crisis Period

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

Big data and analytics will drive patient outcomes in a big way, and the coming years will witness a growing emphasis on healthcare service providers in the business of gathering and processing patient health data.

Creating outcome-oriented financial models to maximize reimbursements in value-based healthcare will be a strategic shift from the traditional fees-for-services model. This implies that pharmaceutical companies will need to devise appropriate measures to optimize costs and improve the quality of patient care.

The relatively new technology for integrating magnetic resonance imaging (MRI) with radiation therapy is becoming increasingly prevalent, with revenues from the MRI-guided radiation therapy systems market exceeding US$ 220 Mn in 2018, according to a recent study by Fact.MR.  This remarkable growth potential of the MRI-guided radiation therapy systems market can be attributed to burgeoning adoption of innovative technologies in the cancer diagnosis & treatment, alongside growing focus on patient-centric care.

For more insights, Request a Sample of the MRI-guided Radiation Therapy Systems Market Report  https://www.factmr.com/connectus/sample?flag=S&rep_id=2572

The study assesses macro and microeconomic factors that define the growth prospects of the MRI-guided radiation therapy systems market. It finds that leading players in the rapidly-growing healthcare sector are vying for new techniques in cancer treatment to compensate for involuntary patient movements and improve precision to a much higher degree. In addition, the paradigm shift in preference of cancer patients towards radiation therapies, from invasive to non-invasive procedures, is expected to remain instrumental in adoption of MRI-guided radiation therapy systems in cancer care.

Leading cancer research institutes are exploring the potential for MRI in radiation therapy in order to enhance the efficiency and precision of existing cancer treatments. However, integrating MRI technology, which uses magnetic field to produce images, with an all-metal linear accelerator in radiation therapy devices requires exceptional technological expertise and a strong international consortium. Currently, Elekta and Viewray are the only two companies that have a strong foothold in the MRI-guided radiation therapy systems market, and it may be a while until new entrants make foray into the market,” says Fact.MR.

Global MRI-guided Radiation Therapy Systems   Market Analysis 2013-2017 and Forecast 2018-2028, By Region

Key Regions Analyzed
• North America
• Latin America
• Europe
• Asia-Pacific
• Middle East & Africa


Key Country-wise Inclusions
 US MRI-guided Radiation Therapy Systems Market
• Canada MRI-guided Radiation Therapy Systems Sales
• Germany MRI-guided Radiation Therapy Systems Production
• UK MRI-guided Radiation Therapy Systems Industry
• France MRI-guided Radiation Therapy Systems Market
• Japan MRI-guided Radiation Therapy Systems Supply Assessment

For comprehensive insights on this market adoption, ask an analyst here https://www.factmr.com/connectus/sample?flag=AE&rep_id=2572

Global MRI-guided Radiation Therapy Systems   Market Analysis 2013-2017 and Forecast 2018-2028, by End User

Hospitals
Radiotherapy Centers
Cancer Research Institutes 

Global MRI-guided Radiation Therapy Systems   Market Analysis 2013-2017 and Forecast 2018-2028, by Product

Linac MR-RT Systems
Software

Global MRI-guided Radiation Therapy Systems   Market Analysis 2013-2017 and Forecast 2018-2028, by MR Dimensions 

0.5 Tesla MR Scanner
1.5 Tesla MR Scanner

Hospitals Remain the Target Customers for Market Players

The study opines that hospital, with over 51% revenue share, will remain the target customer for players in the MRI-guided radiation therapy systems market in 2019. Opportunities abound for of MRI-guided radiation therapy system developers,, with ongoing clinical development of high-tech procedures exploiting Linac MR-RT (Linear accelerators integrated with magnetic resonance radiotherapy).

The study also finds that radiotherapy centers are adopting technologically-advanced MRI-compatible radiation models, to explore numerous possibilities to make radiotherapy treatment more effective. Market players are focusing on building a successful consortium with the help of physicians, clinicians, as well as Original Equipment Manufacturers (OEMs), to tap opportunities in the radiation therapy centers.

Full Access of this Exclusive Report is Available at- https://www.factmr.com/checkout/2572/S

The study opines that the increasing healthcare expenditure in the United States (U.S.) will remain a key growth determinant of the MRI-guided radiation therapy systems market in North America. In 2017, the per capita health expenditure was over US$10,000 in the U.S., recording an increase of nearly 4% over 2016, according to studies. In addition, an alarming rise in the prevalence of cancer in the U.S. will reflect in a significant demand for MRI-guided radiation therapy systems in North America.

According to the study, North America accounted for 45% sales of MRI-guided radiation therapy systems in 2018. Healthcare organizations in the region are investing heavily in tech-driven radiation treatments for cancer. While demand remains robust in developed markets, developing economies are also emerging as attractive markets for MRI-guided radiation therapy systems. Increasing government investments in healthcare infrastructure in the region, are expected to create new opportunities for the players in the MRI-guided radiation therapy systems market.

Explore Fact.MR’s Coverage on the Healthcare Domain

Dual Therapy Stent Market: A recent study by Fact.MR on the Dual Therapy Stent Market offers a 10-year forecast analysis for the period 2017 to 2027. The study analyzes key trends that are currently influencing the growth of the market. This report covers key dynamics, including drivers, restraints, and opportunities for leading market players along with key stakeholders and emerging players.

Phototherapy Devices Market: Fact.MR’s extensive coverage on the Phototherapy Devices Market offers in-depth insights about the prominent growth dynamics that are likely to aid the expansion of growth prospects in the near future. Data has been presented in the form of key segments across prominent geographies, along with important information concerning key manufacturers operating within the industry.

Radiotherapy Devices Market: The Radiotherapy Devices Market study published by Fact.MR offers an unbiased analysis of the prominent drivers, opportunities and trends expected to shape future expansion outlook. The report provides a comprehensive assessment on the prominent segments and geographies which are likely to benefit market players in the forthcoming years.

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:

Unit No: AU-01-H Gold Tower (AU),

Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,

Dubai, United Arab Emirates

Email: [email protected]

Visit Our Website: https://www.factmr.com

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

COVID-19 to Substantially Increase the Demand for 3D Printing Medical Devices Market from Key End-use Industry Sectors Unveils Fact.MR

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

Mass technological transformation of the global healthcare industry has left key market participants struggling to traverse the complexities of medical and life sciences. Given the shifting dynamics of the global healthcare sector, pharma and biotech companies are taking measured efforts to improve patient outcomes in an effective manner, while keeping a careful watch on the bottom line.

The global 3D printing medical devices market is expected to exceed US$ 1,700 Mn in revenues by 2022-end, according to a recent research by Fact.MR. The global 3D printing medical devices market is poised to exhibit a high double-digit CAGR during 2017 to 2022. Introduction of 3D-printed tablets has paved new opportunities for 3D-printing technology, increasing its application across the pharmaceutical industry. Numerous collaborations have been witnessed worldwide, between academic institutions and major players in the market, who are investing heavily in R&D activities. 3D-printing technology has been revolutionizing the preclinical drug testing, making the testing on 3D-printed organs convenient, thereby resulting into the provision of a substitute for animal testing. This technology is also making it easy for surgeons to improve the complicated procedures’ success rate. The aforementioned factors are expected to augment demand for 3D printing medical devices in the years to come.

Potential of 3D-printing in transforming medical devices’ use to treat various diseases is impacting the healthcare sector, enabling construction of non-implantable and implantable medical devices, and cost-effective customizable medical devices. Rise in demand for medical devices that match a patient’s anatomy in orthopedic, and maxillofacial surgery is favoring expansion of medical 3D-printing industry. Facilitating surgeons in planning surgeries, 3D printing medical devices help in lowering operative risks encountered during complex procedures, reduce duration of anesthesia exposure, decrease risk of infection, enable patients in recovering faster, and dramatically reduce time of hospital stay. These factors might further impact the market growth over the forecast period.

For more insights, Request a Sample of 3D Printing Medical Devices Market Report https://www.factmr.com/connectus/sample?flag=S&rep_id=248

Market Taxonomy

By Product Type

  • 3D Printers
  • 3D Bio-Printers
  • Materials
  • Software & Services

By End User

  • Hospitals
  • Academic Institutes
  • Contract Research Organizations
  • Pharma and Biotech Companies

By Technology

  • Laser Beam Melting
  • Photo polymerization
  • Three-Dimensional Printing
  • Electron Beam Melting
  • Droplet Deposition

By Application

  • Implants
  • Tissue Engineering
  • External Wearable Devices

Full Access of this Exclusive Report is Available at- https://www.factmr.com/checkout/248/S

6 Key Estimations for Future of 3D printing medical devices market

  1. Followed by tissue engineering, implants will continue to be the most lucrative application of the 3D-printing medical devices, in terms of revenues. Sale of 3D-printing medical devices for application in building external wearable devices is estimated to exhibit a comparatively lower CAGR through 2022.
  2. Software & services are anticipated to remain preferred among products in the global market. Revenues from software & services are expected to account for more than one-third share of the market throughout the forecast period. In addition, sales of 3D-printing materials will exhibit the highest CAGR through 2022.
  3. Photo polymerization is projected to remain the largest adopted technology in the global market for 3D-printing medical devices, followed by the laser beam melting technology. In addition, sales of electron beam melting technology, and three-dimensional printing technology are expected to exhibit a similar CAGR through 2022.
  4. On the basis of end-users, hospitals will remain dominant in the market, with sales poised to exceed revenues worth US$ 1,000 Mn by 2022-end.
  5. Asia-Pacific excluding Japan (APEJ) will emerge as the fastest expanding market for 3D-printing medical devices during the forecast period. In terms of revenues, North America is expected to be the most lucrative region for growth of the market.
  6. The report profiles key players operating in the market, which include Cyfuse Biomedical K.K., Stratasys Ltd., SLM Solutions Group AG, Renishaw plc, Groupe Gorgé SA, Organovo Holdings, Inc., Materialise NV, EnvisionTEC GmbH, General Electric Company, Carbon, Inc., Biomedical Modeling Inc., and 3D Systems Corporation.

For comprehensive insights on this market adoption, ask an analyst here https://www.factmr.com/connectus/sample?flag=AE&rep_id=248

Explore Fact.MR’s Coverage on the Healthcare Domain

Electrosurgery Devices Market: A recent study by Fact.MR on the Electrosurgery Devices Market offers a 10-year forecast analysis for the period 2017 to 2022. The study analyzes key trends that are currently influencing the growth of the market. This report covers key dynamics, including drivers, restraints, and opportunities for leading market players along with key stakeholders and emerging players.

Coatings for Medical Devices Market: Fact.MR’s extensive coverage on the Coatings for Medical Devices Market offers in-depth insights about the prominent growth dynamics that are likely to aid the expansion of growth prospects in the near future. Data has been presented in the form of key segments across prominent geographies, along with important information concerning key manufacturers operating within the industry.

ENT Medical Devices Market: The ENT Medical Devices Market study published by Fact.MR offers an unbiased analysis of the prominent drivers, opportunities and trends expected to shape future expansion outlook. The report provides a comprehensive assessment on the prominent segments and geographies which are likely to benefit market players in the forthcoming years.

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:

Unit No: AU-01-H Gold Tower (AU),

Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,

Dubai, United Arab Emirates

Email: [email protected]

Visit Our Website: https://www.factmr.com

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

DOORwaY-90 Study for SIR-Spheres® Therapy as 1st-line Treatment for Hepatocellular Carcinoma Enrolls First Patient

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

DOORwaY-90 Study: Sirtex Medical (“Sirtex”), a leading manufacturer of targeted liver cancer therapies, announced that the first patient has been enrolled in DOORwaY90, a study evaluating the safety and efficacy of selective internal radiation therapy (SIRT) using SIR-Spheres® Y-90 resin microspheres in patients with unresectable hepatocellular carcinoma (HCC).

DOORwaY90, which stands for “Duration of Objective Response with Arterial Y-90,” is the first prospective, U.S.-based multicenter, open-label single arm study of its kind. The study will assess the duration of response (DoR) and objective response rate (ORR) of SIR-Spheres. It is being led by co-principal investigators Cheenu Kappadath, PhD and Dr. Armeen Mahvash. Study enrollment is underway, with the first patient enrolled at Inland Imaging Associates and Providence Sacred Heart Medical Center in Spokane, Washington.

“We are thrilled to enroll the first patient in DOORwaY90,” said Dr. Mark A. Turco, Global Chief Medical Officer and EVP of Research and Development for Sirtex. “This clinical trial studying a heterogeneous population of patients with HCC using personalized dosimetry planning has the potential to advance the treatment of HCC patients worldwide. We are deeply thankful to every clinical investigator and patient who will be part of this groundbreaking journey.”

With a planned enrollment of 100 subjects across 15 sites both academic and non-academic, DOORwaY90 is enrolling patients with Barcelona Clinic Liver Cancer (BCLC) Stage A, B1 and B2 who are not eligible for resection or ablation at the time of study entry. The study is unique because it is the first FDA-approved U.S.-based prospective trial to utilize and delineate personalized dosimetry treatment planning and to define actionable post-treatment dosimetric verification for endpoint assessment.

“It’s important for physicians to have confidence that their planned Y-90 dose is being delivered in the right amount and to the right place,” said Dr. Douglas Murrey, Vascular and Interventional Radiologist at Inland Imaging Associates and Providence Sacred Heart Medical Center in Spokane, Washington. “The personalized dosimetry component of the DOORwaY90 study will provide meaningful insights to advance our practice and patient outcomes.”

HCC is often diagnosed when potentially curative resection or transplantation is not feasible. SIRT has the potential to deliver a lethal dose of radiation to hepatic tumors, while sparing surrounding healthy liver tissue. In countries outside the U.S., SIRT has been successfully used to bridge patients to transplantation or downstage HCC to within transplantation criteria or resection.

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

Acutus Medical Announces CE Mark Approval for Suite of Next Generation EP Products in Europe

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced CE Mark Approval for a broad suite of EP products that includes the AcQCross™ family of universal transseptal crossing devices, the next generation AcQGuide® MAX and VUE large bore delivery sheaths and the next generation AcQMap® mapping catheter.

These products are designed to streamline procedural workflow in all left heart procedures and further improve ease-of-use of Acutus’ proprietary non-contact mapping technology, which allows electrophysiologists to quickly and accurately map the most complex atrial arrhythmias in minutes.

“Our R&D investments are translating into meaningful clinical innovations, as we build a comprehensive portfolio of therapy management solutions that make procedures safer, simpler and more effective,” said Vince Burgess, President and CEO of Acutus Medical. “We remain steadfast in our commitment to improve the treatment of complex atrial arrhythmias, and the European launch of our next generation access and diagnostic technologies is another step in that direction.”

Today’s approvals expand on the company’s extensive therapy guidance and ablation product lines already approved in Europe. Newly CE marked products include:

  • AcQCross family of universal transseptal crossing devices. This is the first and only transseptal puncture system specifically engineered to pair and mate seamlessly with market leading sheaths in addition to Acutus’ own offerings. Transseptal crossing devices are used in a range of electrophysiology and structural heart procedures, such as atrial fibrillation ablation, left atrial appendage occlusions, and transcatheter mitral valve repair. The new AcQCross family of catheters include versions that are length-, diameter- and tip-matched and designed to lock into the hub of sheaths now used in the vast majority of left heart procedures, including those provided by Acutus and by other vendors. This unique compatibility allows physicians to utilize AcQCross with their sheath of choice during virtually any left heart procedure.
  • AcQGuide MAX and VUE steerable sheaths. These sheaths provide improved handling and deliverability that are designed to facilitate even faster anatomy reconstruction and mapping acquisition times when used in conjunction with Acutus’ AcQMap 3D imaging and mapping system. The VUE sheath, which is expected to be launched later this year, will also include tip electrodes intended to facilitate catheter localization and improved workflow in procedures where physicians desire to limit the use of fluoroscopy.
  • Next-generation AcQMap 3D imaging and mapping catheter. The only integrated high-resolution ultrasound-based imaging and non-contact mapping catheter capable of capturing cardiac imaging information in addition to cardiac electrical activation mapping is enhanced with improved torque response, handling, and maneuverability. AcQMap Catheter’s advanced transducer and electrode design, when partnered with the AcQMap System, allows electrophysiologists to create an anatomical map of the atrial chambers of the heart and map simple and complex electrical patters of the heart in sinus and complex arrhythmias. Improved visualization of the arrhythmia in cardiac tissue allows physicians to employ new approaches to cardiac ablation as evidenced in a recently published article online in the Heart Rhythm Society Journal. Independent investigators found that 87.5% of patients experienced freedom from AF at two years after a single ablation procedure informed by Acutus’ AcQMap System1.

In Europe, there are approximately 350,000 cardiac ablations annually. This procedure volume is expected to grow to 475,000 by 20252. The increasing prevalence of complex arrythmias and the associated burden on patients and healthcare providers requires new solutions from access to diagnosis to therapy.

The AcQCross Universal Transseptal Access System and the second-generation AcQMap 3D imaging and mapping catheter are now commercially available in Europe and the United States. The AcQGuide VUE and second generation AcQGuide MAX are approved in Europe but are not cleared for sale in the United States. For more information, visit www.acutusmedical.com/us/.


References
1 Shi R, et al, An Individualised Ablation Strategy to Treat Persistent Atrial Fibrillation: Core-to-Boundary Approach Guided by Charge-Density Mapping, Heart Rhythm (2021), doi: https://doi.org/10.1016/ j.hrthm.2021.02.014.
22019 Millennium Research Group: Electrophysiology Mapping and Ablation Devices | Market Analysis | Europe (Supplemental) | 2019

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

Global Surgical Lasers Market to Reach $10.1 Billion by 2027

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

Global Surgical Lasers Market Industry Report – https://www.reportlinker.com/p06033049/?utm_source=GNW

1 Billion by 2027, growing at a CAGR of 9.7% over the analysis period 2020-2027. Solid-State Laser Systems, one of the segments analyzed in the report, is projected to record a 9.2% CAGR and reach US$3.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Gas Laser Systems segment is readjusted to a revised 10.6% CAGR for the next 7-year period.

– The U.S. Market is Estimated at $1.4 Billion, While China is Forecast to Grow at 12.8% CAGR
– The Surgical Lasers market in the U.S. is estimated at US$1.4 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2027 trailing a CAGR of 12.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.7% and 8.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.6% CAGR.
– Diode Laser Systems Segment to Record 9.7% CAGR
– In the global Diode Laser Systems segment, USA, Canada, Japan, China and Europe will drive the 9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$833.8 Million in the year 2020 will reach a projected size of US$1.5 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.5 Billion by the year 2027, while Latin America will expand at a 11.1% CAGR through the analysis period.

Select Competitors (Total 42 Featured) –

  • Abbott Laboratories, Inc.
  • Alma lasers
  • Biolitec AG
  • Bison Medical Co. Ltd
  • Boston Scientific Corporation
  • Cynosure Inc.
  • Lumenis
  • Sharp light Technology
  • Spectranetics Corporation
  • Syneron Medical Ltd

Read the full report: https://www.reportlinker.com/p06033049/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Surgical Lasers by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 2: World Historic Review for Surgical Lasers by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Surgical Lasers by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Solid-State Laser
Systems by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Solid-State Laser Systems by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Solid-State Laser
Systems by Geographic Region – Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

Table 7: World Current & Future Analysis for Gas Laser Systems
by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 8: World Historic Review for Gas Laser Systems by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Gas Laser Systems by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Diode Laser
Systems by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for Diode Laser Systems by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Diode Laser Systems by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Other Types by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 14: World Historic Review for Other Types by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 15: World 15-Year Perspective for Other Types by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Ambulatory
Surgical Centers by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets – Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Ambulatory Surgical Centers
by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Ambulatory Surgical
Centers by Geographic Region – Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

Table 19: World Current & Future Analysis for Hospitals by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 20: World Historic Review for Hospitals by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 21: World 15-Year Perspective for Hospitals by Geographic
Region – Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Specialty Clinics
by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 23: World Historic Review for Specialty Clinics by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Specialty Clinics by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Aesthetic by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 26: World Historic Review for Aesthetic by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 27: World 15-Year Perspective for Aesthetic by Geographic
Region – Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 28: World Current & Future Analysis for Surgical by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 29: World Historic Review for Surgical by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 30: World 15-Year Perspective for Surgical by Geographic
Region – Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 31: World Current & Future Analysis for Other
Applications by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 32: World Historic Review for Other Applications by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 33: World 15-Year Perspective for Other Applications by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 34: USA Current & Future Analysis for Surgical Lasers by
Type – Solid-State Laser Systems, Gas Laser Systems, Diode
Laser Systems and Other Types – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 35: USA Historic Review for Surgical Lasers by Type –
Solid-State Laser Systems, Gas Laser Systems, Diode Laser
Systems and Other Types Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 36: USA 15-Year Perspective for Surgical Lasers by Type –
Percentage Breakdown of Value Sales for Solid-State Laser
Systems, Gas Laser Systems, Diode Laser Systems and Other Types
for the Years 2012, 2020 & 2027

Table 37: USA Current & Future Analysis for Surgical Lasers by
End-Use – Ambulatory Surgical Centers, Hospitals and Specialty
Clinics – Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 38: USA Historic Review for Surgical Lasers by End-Use –
Ambulatory Surgical Centers, Hospitals and Specialty Clinics
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 39: USA 15-Year Perspective for Surgical Lasers by
End-Use – Percentage Breakdown of Value Sales for Ambulatory
Surgical Centers, Hospitals and Specialty Clinics for the Years
2012, 2020 & 2027

Table 40: USA Current & Future Analysis for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 41: USA Historic Review for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 42: USA 15-Year Perspective for Surgical Lasers by
Application – Percentage Breakdown of Value Sales for
Aesthetic, Surgical and Other Applications for the Years 2012,
2020 & 2027

CANADA
Table 43: Canada Current & Future Analysis for Surgical Lasers
by Type – Solid-State Laser Systems, Gas Laser Systems, Diode
Laser Systems and Other Types – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 44: Canada Historic Review for Surgical Lasers by Type –
Solid-State Laser Systems, Gas Laser Systems, Diode Laser
Systems and Other Types Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 45: Canada 15-Year Perspective for Surgical Lasers by
Type – Percentage Breakdown of Value Sales for Solid-State
Laser Systems, Gas Laser Systems, Diode Laser Systems and Other
Types for the Years 2012, 2020 & 2027

Table 46: Canada Current & Future Analysis for Surgical Lasers
by End-Use – Ambulatory Surgical Centers, Hospitals and
Specialty Clinics – Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 47: Canada Historic Review for Surgical Lasers by End-Use –
Ambulatory Surgical Centers, Hospitals and Specialty Clinics
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 48: Canada 15-Year Perspective for Surgical Lasers by
End-Use – Percentage Breakdown of Value Sales for Ambulatory
Surgical Centers, Hospitals and Specialty Clinics for the Years
2012, 2020 & 2027

Table 49: Canada Current & Future Analysis for Surgical Lasers
by Application – Aesthetic, Surgical and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 50: Canada Historic Review for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 51: Canada 15-Year Perspective for Surgical Lasers by
Application – Percentage Breakdown of Value Sales for
Aesthetic, Surgical and Other Applications for the Years 2012,
2020 & 2027

JAPAN
Table 52: Japan Current & Future Analysis for Surgical Lasers
by Type – Solid-State Laser Systems, Gas Laser Systems, Diode
Laser Systems and Other Types – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 53: Japan Historic Review for Surgical Lasers by Type –
Solid-State Laser Systems, Gas Laser Systems, Diode Laser
Systems and Other Types Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 54: Japan 15-Year Perspective for Surgical Lasers by Type –
Percentage Breakdown of Value Sales for Solid-State Laser
Systems, Gas Laser Systems, Diode Laser Systems and Other Types
for the Years 2012, 2020 & 2027

Table 55: Japan Current & Future Analysis for Surgical Lasers
by End-Use – Ambulatory Surgical Centers, Hospitals and
Specialty Clinics – Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 56: Japan Historic Review for Surgical Lasers by End-Use –
Ambulatory Surgical Centers, Hospitals and Specialty Clinics
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 57: Japan 15-Year Perspective for Surgical Lasers by
End-Use – Percentage Breakdown of Value Sales for Ambulatory
Surgical Centers, Hospitals and Specialty Clinics for the Years
2012, 2020 & 2027

Table 58: Japan Current & Future Analysis for Surgical Lasers
by Application – Aesthetic, Surgical and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 59: Japan Historic Review for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 60: Japan 15-Year Perspective for Surgical Lasers by
Application – Percentage Breakdown of Value Sales for
Aesthetic, Surgical and Other Applications for the Years 2012,
2020 & 2027

CHINA
Table 61: China Current & Future Analysis for Surgical Lasers
by Type – Solid-State Laser Systems, Gas Laser Systems, Diode
Laser Systems and Other Types – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 62: China Historic Review for Surgical Lasers by Type –
Solid-State Laser Systems, Gas Laser Systems, Diode Laser
Systems and Other Types Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 63: China 15-Year Perspective for Surgical Lasers by Type –
Percentage Breakdown of Value Sales for Solid-State Laser
Systems, Gas Laser Systems, Diode Laser Systems and Other Types
for the Years 2012, 2020 & 2027

Table 64: China Current & Future Analysis for Surgical Lasers
by End-Use – Ambulatory Surgical Centers, Hospitals and
Specialty Clinics – Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 65: China Historic Review for Surgical Lasers by End-Use –
Ambulatory Surgical Centers, Hospitals and Specialty Clinics
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 66: China 15-Year Perspective for Surgical Lasers by
End-Use – Percentage Breakdown of Value Sales for Ambulatory
Surgical Centers, Hospitals and Specialty Clinics for the Years
2012, 2020 & 2027

Table 67: China Current & Future Analysis for Surgical Lasers
by Application – Aesthetic, Surgical and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 68: China Historic Review for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 69: China 15-Year Perspective for Surgical Lasers by
Application – Percentage Breakdown of Value Sales for
Aesthetic, Surgical and Other Applications for the Years 2012,
2020 & 2027

EUROPE
Table 70: Europe Current & Future Analysis for Surgical Lasers
by Geographic Region – France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2020 through 2027 and %
CAGR

Table 71: Europe Historic Review for Surgical Lasers by
Geographic Region – France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets – Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 72: Europe 15-Year Perspective for Surgical Lasers by
Geographic Region – Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2012, 2020 & 2027

Table 73: Europe Current & Future Analysis for Surgical Lasers
by Type – Solid-State Laser Systems, Gas Laser Systems, Diode
Laser Systems and Other Types – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 74: Europe Historic Review for Surgical Lasers by Type –
Solid-State Laser Systems, Gas Laser Systems, Diode Laser
Systems and Other Types Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 75: Europe 15-Year Perspective for Surgical Lasers by
Type – Percentage Breakdown of Value Sales for Solid-State
Laser Systems, Gas Laser Systems, Diode Laser Systems and Other
Types for the Years 2012, 2020 & 2027

Table 76: Europe Current & Future Analysis for Surgical Lasers
by End-Use – Ambulatory Surgical Centers, Hospitals and
Specialty Clinics – Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 77: Europe Historic Review for Surgical Lasers by End-Use –
Ambulatory Surgical Centers, Hospitals and Specialty Clinics
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 78: Europe 15-Year Perspective for Surgical Lasers by
End-Use – Percentage Breakdown of Value Sales for Ambulatory
Surgical Centers, Hospitals and Specialty Clinics for the Years
2012, 2020 & 2027

Table 79: Europe Current & Future Analysis for Surgical Lasers
by Application – Aesthetic, Surgical and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 80: Europe Historic Review for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 81: Europe 15-Year Perspective for Surgical Lasers by
Application – Percentage Breakdown of Value Sales for
Aesthetic, Surgical and Other Applications for the Years 2012,
2020 & 2027

FRANCE
Table 82: France Current & Future Analysis for Surgical Lasers
by Type – Solid-State Laser Systems, Gas Laser Systems, Diode
Laser Systems and Other Types – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 83: France Historic Review for Surgical Lasers by Type –
Solid-State Laser Systems, Gas Laser Systems, Diode Laser
Systems and Other Types Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 84: France 15-Year Perspective for Surgical Lasers by
Type – Percentage Breakdown of Value Sales for Solid-State
Laser Systems, Gas Laser Systems, Diode Laser Systems and Other
Types for the Years 2012, 2020 & 2027

Table 85: France Current & Future Analysis for Surgical Lasers
by End-Use – Ambulatory Surgical Centers, Hospitals and
Specialty Clinics – Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 86: France Historic Review for Surgical Lasers by End-Use –
Ambulatory Surgical Centers, Hospitals and Specialty Clinics
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 87: France 15-Year Perspective for Surgical Lasers by
End-Use – Percentage Breakdown of Value Sales for Ambulatory
Surgical Centers, Hospitals and Specialty Clinics for the Years
2012, 2020 & 2027

Table 88: France Current & Future Analysis for Surgical Lasers
by Application – Aesthetic, Surgical and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 89: France Historic Review for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 90: France 15-Year Perspective for Surgical Lasers by
Application – Percentage Breakdown of Value Sales for
Aesthetic, Surgical and Other Applications for the Years 2012,
2020 & 2027

GERMANY
Table 91: Germany Current & Future Analysis for Surgical Lasers
by Type – Solid-State Laser Systems, Gas Laser Systems, Diode
Laser Systems and Other Types – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 92: Germany Historic Review for Surgical Lasers by Type –
Solid-State Laser Systems, Gas Laser Systems, Diode Laser
Systems and Other Types Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 93: Germany 15-Year Perspective for Surgical Lasers by
Type – Percentage Breakdown of Value Sales for Solid-State
Laser Systems, Gas Laser Systems, Diode Laser Systems and Other
Types for the Years 2012, 2020 & 2027

Table 94: Germany Current & Future Analysis for Surgical Lasers
by End-Use – Ambulatory Surgical Centers, Hospitals and
Specialty Clinics – Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 95: Germany Historic Review for Surgical Lasers by
End-Use – Ambulatory Surgical Centers, Hospitals and Specialty
Clinics Markets – Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 96: Germany 15-Year Perspective for Surgical Lasers by
End-Use – Percentage Breakdown of Value Sales for Ambulatory
Surgical Centers, Hospitals and Specialty Clinics for the Years
2012, 2020 & 2027

Table 97: Germany Current & Future Analysis for Surgical Lasers
by Application – Aesthetic, Surgical and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 98: Germany Historic Review for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 99: Germany 15-Year Perspective for Surgical Lasers by
Application – Percentage Breakdown of Value Sales for
Aesthetic, Surgical and Other Applications for the Years 2012,
2020 & 2027

ITALY
Table 100: Italy Current & Future Analysis for Surgical Lasers
by Type – Solid-State Laser Systems, Gas Laser Systems, Diode
Laser Systems and Other Types – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 101: Italy Historic Review for Surgical Lasers by Type –
Solid-State Laser Systems, Gas Laser Systems, Diode Laser
Systems and Other Types Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 102: Italy 15-Year Perspective for Surgical Lasers by
Type – Percentage Breakdown of Value Sales for Solid-State
Laser Systems, Gas Laser Systems, Diode Laser Systems and Other
Types for the Years 2012, 2020 & 2027

Table 103: Italy Current & Future Analysis for Surgical Lasers
by End-Use – Ambulatory Surgical Centers, Hospitals and
Specialty Clinics – Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 104: Italy Historic Review for Surgical Lasers by End-Use –
Ambulatory Surgical Centers, Hospitals and Specialty Clinics
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 105: Italy 15-Year Perspective for Surgical Lasers by
End-Use – Percentage Breakdown of Value Sales for Ambulatory
Surgical Centers, Hospitals and Specialty Clinics for the Years
2012, 2020 & 2027

Table 106: Italy Current & Future Analysis for Surgical Lasers
by Application – Aesthetic, Surgical and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 107: Italy Historic Review for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 108: Italy 15-Year Perspective for Surgical Lasers by
Application – Percentage Breakdown of Value Sales for
Aesthetic, Surgical and Other Applications for the Years 2012,
2020 & 2027

UNITED KINGDOM
Table 109: UK Current & Future Analysis for Surgical Lasers by
Type – Solid-State Laser Systems, Gas Laser Systems, Diode
Laser Systems and Other Types – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 110: UK Historic Review for Surgical Lasers by Type –
Solid-State Laser Systems, Gas Laser Systems, Diode Laser
Systems and Other Types Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 111: UK 15-Year Perspective for Surgical Lasers by Type –
Percentage Breakdown of Value Sales for Solid-State Laser
Systems, Gas Laser Systems, Diode Laser Systems and Other Types
for the Years 2012, 2020 & 2027

Table 112: UK Current & Future Analysis for Surgical Lasers by
End-Use – Ambulatory Surgical Centers, Hospitals and Specialty
Clinics – Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 113: UK Historic Review for Surgical Lasers by End-Use –
Ambulatory Surgical Centers, Hospitals and Specialty Clinics
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 114: UK 15-Year Perspective for Surgical Lasers by
End-Use – Percentage Breakdown of Value Sales for Ambulatory
Surgical Centers, Hospitals and Specialty Clinics for the Years
2012, 2020 & 2027

Table 115: UK Current & Future Analysis for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 116: UK Historic Review for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 117: UK 15-Year Perspective for Surgical Lasers by
Application – Percentage Breakdown of Value Sales for
Aesthetic, Surgical and Other Applications for the Years 2012,
2020 & 2027

SPAIN
Table 118: Spain Current & Future Analysis for Surgical Lasers
by Type – Solid-State Laser Systems, Gas Laser Systems, Diode
Laser Systems and Other Types – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 119: Spain Historic Review for Surgical Lasers by Type –
Solid-State Laser Systems, Gas Laser Systems, Diode Laser
Systems and Other Types Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 120: Spain 15-Year Perspective for Surgical Lasers by
Type – Percentage Breakdown of Value Sales for Solid-State
Laser Systems, Gas Laser Systems, Diode Laser Systems and Other
Types for the Years 2012, 2020 & 2027

Table 121: Spain Current & Future Analysis for Surgical Lasers
by End-Use – Ambulatory Surgical Centers, Hospitals and
Specialty Clinics – Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 122: Spain Historic Review for Surgical Lasers by End-Use –
Ambulatory Surgical Centers, Hospitals and Specialty Clinics
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 123: Spain 15-Year Perspective for Surgical Lasers by
End-Use – Percentage Breakdown of Value Sales for Ambulatory
Surgical Centers, Hospitals and Specialty Clinics for the Years
2012, 2020 & 2027

Table 124: Spain Current & Future Analysis for Surgical Lasers
by Application – Aesthetic, Surgical and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 125: Spain Historic Review for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 126: Spain 15-Year Perspective for Surgical Lasers by
Application – Percentage Breakdown of Value Sales for
Aesthetic, Surgical and Other Applications for the Years 2012,
2020 & 2027

RUSSIA
Table 127: Russia Current & Future Analysis for Surgical Lasers
by Type – Solid-State Laser Systems, Gas Laser Systems, Diode
Laser Systems and Other Types – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 128: Russia Historic Review for Surgical Lasers by Type –
Solid-State Laser Systems, Gas Laser Systems, Diode Laser
Systems and Other Types Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 129: Russia 15-Year Perspective for Surgical Lasers by
Type – Percentage Breakdown of Value Sales for Solid-State
Laser Systems, Gas Laser Systems, Diode Laser Systems and Other
Types for the Years 2012, 2020 & 2027

Table 130: Russia Current & Future Analysis for Surgical Lasers
by End-Use – Ambulatory Surgical Centers, Hospitals and
Specialty Clinics – Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 131: Russia Historic Review for Surgical Lasers by
End-Use – Ambulatory Surgical Centers, Hospitals and Specialty
Clinics Markets – Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 132: Russia 15-Year Perspective for Surgical Lasers by
End-Use – Percentage Breakdown of Value Sales for Ambulatory
Surgical Centers, Hospitals and Specialty Clinics for the Years
2012, 2020 & 2027

Table 133: Russia Current & Future Analysis for Surgical Lasers
by Application – Aesthetic, Surgical and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 134: Russia Historic Review for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 135: Russia 15-Year Perspective for Surgical Lasers by

Carestream Smart Noise Cancellation SNC ankle captis executive search management consulting leadership board services

Carestream Health Advances X-ray Image Quality with Smart Noise Cancellation

Carestream Smart Noise Cancellation SNC ankle captis executive search management consulting leadership board services

Carestream Health has released Smart Noise Cancellation (SNC), a groundbreaking artificial intelligence (AI)-based technology that greatly improves image quality—producing images that are significantly clearer than with standard processing.

SNC has received FDA 510(k) Clearance and is available as an optional feature with Carestream’s ImageView Software powered by Eclipse—the intelligent image-processing engine behind the company’s innovative imaging software—on DRX-Evolution and DRX-Evolution Plus systems.

“Carestream is a leader in using AI for noise cancellation with X-ray images. Our team of imaging scientists has been able to separate image noise from sharpness and contrast using AI-based algorithms that result in remarkable image quality,” said Jill Hamman, Worldwide Marketing Manager, Global X-ray Solutions at Carestream. “This technology provides improved anatomical clarity, preservation of fine detail and better contrast-to-noise ratio for images acquired at a broad range of exposures, which can help improve diagnostic confidence and alleviate physician fatigue. It also enables radiology professionals to better optimize radiation dose.” Optimizing radiation dose is especially important with neonatal and pediatric diagnostic imaging, where imaging at the lowest possible dose is crucial for young patients.

Separating noise from an image has been a challenge for medical imaging scientists. Traditional noise reduction introduces blurring, which degrades image sharpness and might remove important anatomical information. Conversely, the more an image is sharpened, the more noise may be enhanced. Noise is often an undesirable by-product of image capture and can obscure critical anatomical data. Carestream’s SNC is able to isolate noise to produce images that are significantly clearer than with standard processing.

As the preferred level of noise on X-ray images is subjective—for example, some radiologists expect to see a certain degree of noise in images, which assures them that the patient was not overexposed—Carestream enables imaging professionals to adjust the amount of noise cancellation and exposure to meet their desired image quality.

Carestream Health notes objective testing demonstrated that SNC processing enables a 2x–4x noise reduction in flat image areas, preserves high frequency sharpness and improves contrast detail. Additionally, a blind Clinical Reader Study using board-certified radiologists found that 89.5 percent of all study ratings showed a slight to strong preference for SNC-processed images. Sixty-four percent of the diagnostic quality ratings improved—based on the RadLex rating scale—and 56 percent of these ratings improved from “limited” or “diagnostic” to “exemplary.”

Carestream Health notes when combined with SmartGrid software, Smart Noise Cancellation software promises benefits in gridless imaging where the removal of scatter typically leads to an increase in noise appearance.

“At Carestream, improving image quality is a top priority for our R&D team,” Ms. Hamman said. “Smart Noise Cancellation provides the ability to consistently deliver high-quality diagnostic images for healthcare providers and their patients.”

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

Vector Remote Care: Study Finds Remote Cardiac Monitoring Programs Significantly More Successful When Patients, Not Devices, Are Primary Focus

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

Vector Remote Care today announced the results of a survey on the adoption of remote cardiac monitoring solutions and their impact on managing heart disease in the U.S.

The findings reveal that remote cardiac monitoring (RCM) programs that focus on just remote device data management are missing out on both clinical and financial benefits. In comparison, cardiology practices taking a patient-centric approach focused on data and patient compliance, report improved clinical and financial outcomes.

The survey of over 110 respondents with various roles within a cardiology practice shows nearly 75 percent of respondents believe improving patient outcomes is the first or second priority for their monitoring program.

Nevertheless, narrowing the scope to physician respondents, 43 percent revealed that only 20 percent or less of their heart disease patients are connected (and result in billable reports), which indicates a large margin of missed opportunities for improved clinical and financial outcomes. Despite less-than-optimal connection rates, a strong majority of total respondents—68.75 percent— rate their program as good or excellent.

According to Kristin Stitt, DNP, APRN, Chief Clinical Officer at Vector, “These numbers are not surprising, as RCM is still relatively new. Strong satisfaction with a program that has low connection rates indicates that many practices focus on getting the devices up and running, but are not fully aware of what is possible when you design your program around patient care.”

While 93.52 percent of respondents are doing remote monitoring for rhythm management, about one-third of those practices have less than 60 percent of their patients regularly connected. In addition, fewer than 68 percent of respondents are monitoring for heart failure, and fewer than 19 percent are monitoring for hypertension.

Programs with 80-100 percent of their patients connected are most successful at gathering the revenue needed to cover program costs. Practices with less than 60 percent of patients routinely connected for billable reports clearly see covering costs as a significant challenge.

Electrophysiologist Christopher Porterfield, MD, states, “There are hundreds to thousands of stories where remote monitoring has made it easier to care for patients and, in many cases, to save lives.” Dr. Porterfield assisted with survey development and analysis of the responses.

Additional findings show practices struggle to keep patients engaged in their care, placing a strain on staff and making it impossible for clinical and financial benefits to be fully realized. All respondents view keeping patients connected, reviewing alerts, and preparing reports as their biggest challenges, but practices’ staff doing the monitoring are the most burdened.

Respondents partnering with a third-party vendor cite improved satisfaction in being able to offload time-consuming administrative work. Third party success in enrolling patients, keeping them connected, and collecting appropriate revenue is likely due to a combination of clear goals, streamlined workflows, technology, and support services that ease burdens listed above.

Katie Arnold captis executive search management consulting leadership board services

Katie Arnold Appointed to BOD of InspireMD: Proven Marketing Professional

Katie Arnold captis executive search management consulting leadership board services

Katie Arnold (Kathryn Arnold) has more than two decades of strategy and commercialization experience within the medical device industry.

Katie Arnold joins as the company advances global commercialization and enrollment in the U.S. IDE trial of its novel CGuard EPS technology.

“We are pleased to welcome Katie to the InspireMD Board. She is a proven marketing professional with a track record for delivering flawless launch execution and implementing key business strategies,” commented Paul Stuka, Chairman of the InspireMD Board. “Her wealth of knowledge and strong leadership will be instrumental in guiding our strategic plan and expand our commercial footprint.”

Katie Arnold is the Founder and CEO of SPRIG Consulting, a strategic marketing consulting firm with over a decade of success in the medical space. Since its inception, the firm has engaged with over 200 medical companies ranging from venture-backed startups to Fortune 500 companies.

Prior to founding SPRIG, Ms. Arnold held sales and marketing management roles with Guidant Corporation (acquired by Abbott Laboratories and Boston Scientific) and Kensey Nash Corporation (acquired by Spectranetics Corporation / Royal Philips). She has managed vascular and endovascular businesses, built strong commercial teams, and led numerous successful global product launches.

Additionally, Ms. Arnold is an adjunct faculty member at the Kellogg School of Management at Northwestern University where she teaches a course-specific to medical product commercialization and financing. Ms. Arnold received a bachelor of arts in environmental science from the University of Vermont and a master’s degree from the Kellogg School of Management at Northwestern University.

“I am excited to be joining InspireMD’s board at a time of significant organic growth and expansion through commercial and business development activities,” says Ms. Arnold. “Despite advances in the stenting space, a clear unmet need remains for a solution that effectively treats carotid artery disease. I am very impressed with the unique design of the CGuard stent and the robust clinical data validating its performance. I am excited to work with the management team and the board as we maximize opportunities for the company to reduce the worldwide stroke burden and transform the treatment of carotid artery disease.”

Picture1 captis executive search management consulting leadership board services

CSA Medical Completes Enrollment in Mechanism of Action Study Utilizing the RejuvenAir® System for COPD Patients with Chronic Bronchitis

Picture1 captis executive search management consulting leadership board services

The aim of this study is to determine the mechanism by which Metered CryoSpray (MCS) reduces the density of goblet cells responsible for over-producing mucus and observe re-growth of healthy cilia in the airways.

“In the previous study, we saw meaningful improvements in patient symptoms and quality of life,” said Professor Pallav Shah M.D., from the Royal Brompton, London. “What makes this study different is that we will now be able to provide the cellular rationale for the remodeling response we observed in the feasibility study after treatment with RejuvenAir. In other words, we will prove re-epithelialization and regrowth of healthy airway tissue.”

CSA Medical, the developer of the RejuvenAir System, is currently conducting a pivotal study in twenty sites across the United States. The SPRAY-CB Study is actively enrolling subjects who suffer from the debilitating symptoms of Chronic Bronchitis.

COPD is a long-term, progressive, irreversible lung disease that, over time, makes it difficult to breathe. Chronic Bronchitis (CB), the largest subset of COPD, is characterized by a chronic productive cough. The SPRAY-CB study is investigating a minimally invasive device therapy, Metered CryoSpray (MCS), which utilizes the RejuvenAir® System, a revolutionary cryosurgical device which applies a precise thermal dose of extremely cold, -196C liquid nitrogen to targeted areas within the lungs through an outpatient bronchoscopic procedure.

“Together with the final data from the SPRAY-CB pivotal study, we endeavor to understand not only that metered cryospray reduces the symptoms of chronic bronchitis, but also answer how it works to rejuvenate airways for a better quality of life. Current medications only manage those symptoms, we anticipate the RejuvenAir® System will be the first minimally invasive treatment option for this population,” stated Heather V. Nigro, Senior Vice President of Regulatory, Quality and Clinical Affairs at CSA Medical.